XPC Gene Polymorphisms and Bladder Cancer Risk
Author Information
Author(s): Sak S C, Barrett J H, Paul A B, Bishop D T, Kiltie A E
Primary Institution: Cancer Research UK Clinical Centre in Leeds, St James's University Hospital
Hypothesis
The XPC polymorphisms XPC-PAT, IVS11-6 and Lys939Gln have a role in the aetiology of transitional cell carcinoma of the bladder through modification of risk produced by smoking and occupational exposure.
Conclusion
The study found no association between the XPC polymorphisms and increased risk of bladder transitional cell carcinoma.
Supporting Evidence
- 547 bladder TCC patients and 579 cancer-free controls were analyzed.
- None of the three XPC polymorphisms were significantly associated with increased bladder TCC risk.
- The study had an 83% power to detect an odds ratio of 1.6 for the homozygote variant.
- Genotyping was successful in more than 98% of samples.
- Strong linkage disequilibrium was confirmed among the polymorphisms.
Takeaway
The study looked at certain gene changes to see if they made people more likely to get bladder cancer, but it found that they didn't.
Methodology
A case-control study was conducted with 547 bladder TCC patients and 579 cancer-free controls, analyzing the association between three XPC polymorphisms and bladder cancer susceptibility.
Potential Biases
Recall bias for smoking and occupational exposure.
Limitations
Potential selection bias due to the inclusion of both community and hospital controls.
Participant Demographics
98.6% were Caucasian, with a higher prevalence of smoking and occupational exposure among cases compared to controls.
Statistical Information
Confidence Interval
0.63–1.08
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website